Compounded vs Brand-Name GLP-1: What the Difference Actually Is

Two vials can sit side by side, both labeled “semaglutide,” and be very different products. One came off a pharmaceutical production line, passed FDA review for safety and effectiveness, and ships in a factory-sealed pen. The other was mixed in a compounding pharmacy, was never individually reviewed by the FDA, and might cost a quarter of the price. If you are shopping for GLP-1 weight-loss treatment online in 2026, you will run into both — often without the difference being made clear until checkout, if at all.

This is not a “one is medicine, one is poison” situation, and it is not a “they’re identical, buy the cheap one” situation either. The honest answer lives in the middle, and it depends on regulatory details that most marketing pages skip. This guide walks through exactly what separates brand-name and compounded GLP-1s — approval status, oversight, dosing, cost, and risk — so you can have an informed conversation with a licensed prescriber. And that last part matters: every version of these medications is a prescription drug with real side effects, and the decision about which form (if any) is right for you belongs with your prescriber, not with a pricing page.

What “Brand-Name” Actually Means

Brand-name GLP-1 medications are FDA-approved drugs: Wegovy (semaglutide, approved for chronic weight management in 2021), Ozempic (semaglutide for type 2 diabetes), Zepbound (tirzepatide, approved for weight management in 2023), and Mounjaro (tirzepatide for diabetes). FDA approval means the specific product — the molecule, the manufacturing process, the device, the dosing — went through large clinical trials and ongoing factory inspections.

The famous efficacy numbers belong to these products. In the STEP 1 trial, semaglutide 2.4 mg produced roughly 15 percent average body-weight loss over 68 weeks; in SURMOUNT-1, tirzepatide at the highest dose averaged over 20 percent. Every batch of a brand-name pen must meet the same manufacturing standards the trial drug did, and the pre-filled pen design fixes each dose mechanically, which makes dosing errors rare.

What “Compounded” Actually Means

Compounding is legal, regulated pharmacy practice: a licensed pharmacy prepares a customized medication for a patient, typically because the patient needs something commercially unavailable — a different strength, an allergen-free formulation, or a drug that is in shortage. Compounding pharmacies operate under state boards of pharmacy and federal rules (sections 503A and 503B of the Food, Drug, and Cosmetic Act; 503B “outsourcing facilities” are FDA-registered and inspected against stricter manufacturing standards than 503A pharmacies).

Here is the key point: compounded drugs are not FDA-approved. No compounded semaglutide vial has ever been individually reviewed by the FDA for safety, effectiveness, or quality. That does not automatically make a given vial dangerous — a well-run 503B facility can produce high-quality preparations — but it removes the layer of product-level assurance that approval provides, and quality varies from pharmacy to pharmacy in a way it cannot with a factory-sealed pen.

The Shortage Loophole, and Why It Closed

Compounded GLP-1s exploded between 2022 and 2024 because federal law permits compounding copies of a drug while the FDA lists it as in shortage. Semaglutide and tirzepatide spent long stretches on that list, and telehealth companies built large businesses on compounded versions at $100–$300 per month versus roughly $1,000–$1,350 list price for the brands.

That window has closed. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, which means mass-produced “copies” of the commercial products are no longer permitted under the shortage exception. Compounding continues legally only in narrower lanes — genuinely personalized formulations prescribed for a documented clinical reason. In practice, some vendors lean hard on that personalization language (added B12, unusual strengths) to keep selling; the FDA has signaled skepticism toward copies dressed up with token tweaks. If a website sells you “semaglutide” in 2026 at a too-good price with a two-minute intake form, you should ask hard questions about which lane it is operating in.

The Real Risk Differences

The FDA has received hundreds of adverse-event reports associated with compounded semaglutide and tirzepatide, and several problems come up repeatedly:

• Dosing errors. Compounded GLP-1s usually ship as multi-dose vials with syringes, not fixed-dose pens. Patients drawing “units” from a vial have overdosed by drawing five or ten times the intended amount — the FDA has specifically warned about unit-conversion mistakes causing severe nausea, vomiting, and hospital visits.
• Different salt forms. Some products sold online contain semaglutide sodium or semaglutide acetate — salt forms that are not the base molecule used in the approved drugs and that the FDA has stated have no established safety or efficacy profile. Legitimate compounders should use the base form; many gray-market sellers do not.
• Quality variability. Potency, sterility, and stability depend entirely on the individual pharmacy’s practices. A 503B facility with a clean inspection history is a very different risk than an unknown 503A pharmacy shipping nationwide through a website.
• Counterfeits. Outright fake “GLP-1” vials — sold on social media, from overseas sites, or with no prescription required — are a separate and worse category. No prescription, no pharmacy license, no purchase.

Brand-name products carry the ordinary risks of the drug class itself — gastrointestinal side effects are common, and rarer risks like pancreatitis and gallbladder problems appear in the labeling — but the product-quality and dosing-error layers are largely engineered out.

Cost, Insurance, and the Narrowing Gap

Price drove the compounded boom, but the gap has narrowed. Both manufacturers now sell direct-to-patient programs (NovoCare Pharmacy for Wegovy, LillyDirect for Zepbound) with self-pay pricing for certain doses in the roughly $350–$500 per month range — still expensive, but far below the old list prices. Insurance coverage for weight-management GLP-1s remains inconsistent, so your real-world cost depends on your plan. Before assuming compounded is the only affordable path, price out the manufacturer programs, check your insurance, and ask your prescriber about coverage paperwork; a documented BMI and comorbidity history changes approval odds.

How to Vet What You’re Being Offered: A 6-Point Checklist

• Ask which product it is, by name. “Wegovy” or “Zepbound” means brand-name. “Compounded semaglutide” means compounded. Vague wording like “GLP-1 therapy” deserves a direct question.
• If compounded, ask for the pharmacy’s name and type. Then verify: is it a 503B outsourcing facility (searchable on the FDA’s registration list) or a state-licensed 503A pharmacy (check the state board of pharmacy)?
• Ask what form the semaglutide is. The answer should be the base form — not sodium or acetate salts.
• Confirm a real prescriber interaction. A legitimate service reviews your medical history, labs or vitals, and contraindications, and remains reachable for side-effect management and dose changes.
• Demand dosing instructions in milligrams and units, in writing. If you will use a vial and syringe, have the pharmacist or prescriber walk you through the first draw.
• Walk away from red flags: no prescription required, social-media sellers, “research use” peptides, international shipping workarounds, or prices dramatically below every licensed competitor.

Is compounded semaglutide illegal now?

Not categorically. Compounding remains legal for genuinely individualized prescriptions filled by licensed pharmacies. What ended with the shortage resolutions is the broad permission to mass-compound copies of the commercial products. The gray zone is vendors using thin “personalization” to continue business as usual — regulatory pressure on that practice has been increasing.

Does compounded semaglutide work as well as Wegovy?

There are no large clinical trials of compounded versions — that is precisely what FDA approval required and compounding skips. If a compounded product genuinely contains the same base molecule at an accurate dose, comparable biological effect is plausible, but you are relying on the pharmacy’s quality rather than trial evidence. The 15 percent STEP-trial figure was earned by the approved product.

Why is there no generic semaglutide yet?

Patent protection. Semaglutide’s key patents run into the early 2030s in the United States, so no FDA-approved generic exists here yet. Anything sold today as “generic semaglutide” is either compounded or counterfeit — a useful mental shortcut when evaluating ads.

What should I do if I’m already on a compounded version?

Do not stop abruptly or switch products on your own. Talk to your prescriber about whether staying, switching to a brand-name pen through a manufacturer program, or tapering makes sense for your health and budget. If you switch, dosing needs medical translation — pen doses and vial concentrations do not map one-to-one, and this is exactly where errors happen.